Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Satellos Bioscience ( (TSE:MSCL) ) has shared an update.
Satellos Bioscience Inc. has completed the enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of its oral small molecule drug, SAT-3247, in healthy volunteers. This milestone is part of the company’s mission to deliver transformative therapies for degenerative diseases, specifically Duchenne muscular dystrophy (DMD), marking progress toward presenting Phase 1 data in 2025 and advancing the treatment as a potential novel therapy for muscle regeneration.
More about Satellos Bioscience
Satellos Bioscience Inc. is a public biotech company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders.
YTD Price Performance: -14.42%
Average Trading Volume: 123,351
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $84.44M
For a thorough assessment of MSCL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue